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Introduction: We conducted a phase II study of combination chemo-
therapy with irinotecan (CPT) and cisplatin (CDDP) in patients with 
advanced large-cell neuroendocrine carcinoma (LCNEC) of the lung.
Methods: Patients received irinotecan (60 mg/m2, days 1, 8, and 15) 
and cisplatin (60 mg/m2, day 1) every 4 weeks for up to four cycles. 
The primary endpoint was the response rate. Expected and threshold 
values for the primary endpoint were 50% and 30%.
Results: Forty-four patients were enrolled between January 2005 
and November 2011. The response rate (RR) was 54.5% (95% confi-
dence interval [CI], 38.8–69.6%). The median progression-free sur-
vival time was 5.9 months (95% CI, 5.5–6.3), and the median survival 
time was 15.1 months (95% CI, 11.2–19.0). A central pathological 
review of specimens from 41 patients demonstrated that 30 patients 
had LCNEC but that 10 patients had small-cell lung cancer (SCLC) 
and one had non–small-cell lung cancer with a neuroendocrine struc-
ture. The RR was 46.7% (95% CI, 28.3–65.7%) in the LCNEC group 
and 80% (95% CI, 44.4–97.5%) in the SCLC group (p = 0.0823). 
The median survival time was 12.6 months (95% CI, 9.3–16.0) in the 
LCNEC group and 17.3 months (95% CI, 11.2–23.3) in the SCLC 
group (p = 0.047).
Conclusions: Combination chemotherapy with irinotecan and cis-
platin was active in patients with LCNEC, but the RR and the over-
all survival period among the patients with LCNEC seemed to be 
inferior to those among the patients with SCLC. Small numbers of 
patients were a major limitation in this study.
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(J Thorac Oncol. 2013;8: 980-984)
Large-cell neuroendocrine carcinoma (LCNEC) and small-cell lung cancer (SCLC) are recognized as high-
grade neuroendocrine carcinoma of the lung, and account for 
approximately 15% of all forms of lung cancer. A consider-
able overlap in nuclear size was observed between LCNEC 
and SCLC in a morphometric analysis.1 Thus, a differential 
diagnosis between LCNEC and SCLC using tiny biopsy 
specimens is often difficult. Consequently, prospective clin-
ical trials on chemotherapy in advanced LCNEC have not 
been reported. LCNEC shares many similarities with SCLC 
in terms of not only structure, immunohistochemistry, and 
molecular biology, but also treatment;2 several studies have 
shown that LCNEC responds to cisplatin-based chemothera-
peutic regimens similar to those used for SCLC.3,4 However, 
as LCNEC is a poorly recognized and underdiagnosed 
entity, it is frequently mistaken for poorly differentiated 
non–small-cell lung cancer (NSCLC), atypical carcinoid, or 
intermediate cell-type SCLC.5,6 In one previous study that 
included 75 patients, only 44 (53%) were correctly diag-
nosed as having LCNEC at the outset, whereas 31 (47%) 
were misdiagnosed as having other NSCLCs.7 Such diffi-
culty is attributable to the obscure structure of neuroendo-
crine tumors at the light microscopy level, especially when 
cytology or small biopsy samples are being examined.5 As 
a result, no optimal treatment for patients with LCNEC has 
been indicated as yet, and no evidence exists as to whether 
affected patients might benefit from chemotherapeutic pro-
tocols designed for NSCLC or SCLC.
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Combination chemotherapy consisting of irinotecan 
(CPT) and cisplatin (CDDP) is active against both NSCLC 
and SCLC.8–12 Taking these rationales into consideration, we 
conducted a multicenter phase II study of CPT and CDDP in 
patients with advanced LCNEC.
PATIENTS AND METHODS
Patient Population and Treatment Plan
Patients were required to have histologically confirmed 
advanced-stage LCNEC. Recurrences after surgical resection 
were permitted. Other criteria included an age of 20 to 75 
years, an Eastern Cooperative Oncology Group performance 
status of 0 or 1, measurable disease, a PaO
2
 at room air 65 Torr 
or more, and adequate organ function. Key exclusion criteria 
included prior chemotherapy, interstitial pneumonia as deter-
mined by chest radiograph, and symptomatic brain metasta-
ses. All the patients were required to provide written informed 
consent, and the Institutional Review Board approved the 
protocol.
Patients received 60 mg/m2 of CDDP on day 1 and 
60 mg/m2 of CPT on days 1, 8, and 15 every 4 weeks for up to 
four cycles if neither unacceptable toxicity nor tumor progres-
sion were observed.
Study Evaluation
Imaging studies were scheduled to assess the objective 
response every 2 months. Diagnostic specimens including 
hematoxylin-eosin staining and immunohistochemistry for 
neuroendocrine markers were centrally reviewed by six expert 
pathologists (TK, MN, YI, KI, GI, and KT) who were blinded 
to the patients’ clinical information. The pathology panel 
members performed the pathology review independently, 
and a final diagnosis was established by mutual consent. 
Histologic diagnostic criteria for LCNEC included organoid 
nesting, trabecular growth, and rosette-like and palisading 
patterns, which suggest neuroendocrine differentiation. The 
neuroendocrine features need to be confirmed by immunohis-
tochemical markers, such as chromogranin, synaptophysin, 
and CD56.
The Response Evaluation Criteria in Solid Tumors 
guidelines, version 1.0, was used to evaluate antitumor activ-
ity.13 Toxicity was graded according to the National Cancer 
Institute Common Toxicity Criteria, version 2.0.
Study Design and Statistical Analysis
This trial was designed as a multicenter, prospec-
tive, single-arm phase II study. The primary endpoint of this 
study was the response rate (RR) in the eligible patients with 
advanced LCNEC diagnosed by institutional pathologists. The 
secondary endpoints included overall survival (OS), progres-
sion-free survival (PFS), and toxicity. In accordance with the 
minimax two-stage phase II study design reported by Simon,14 
the treatment program was designed to refuse RRs of 30% 
(P0) and to provide a significance level of 0.05 with a statisti-
cal power of 80% for assessing the activity of the regimen as 
a 50% RR (P1). The upper limit for first-stage drug rejection 
was six responses in the 19 assessable patients; the upper limit 
for second-stage rejection was 16 responses in a cohort of 39 
assessable patients.
The OS was defined as the interval between enrollment 
in this study and death or the final follow-up visit. The OS and 
PFS were estimated using the Kaplan–Meier analysis method. 
Exploratory subgroup analyses for RR, OS, and PFS were 
planned according to the results of the central pathological 
review. Survival data were compared among groups using a 
log-rank test. All the reported p values were two-sided. This 
study was registered with the UMIN Clinical Trials Registry 
(number UMIN000004796).
RESULTS
A total of 44 patients from 11 Japanese institutes were 
enrolled between January 2005 and November 2011. All 44 
patients were eligible for inclusion. The patient characteris-
tics are listed in Table 1. Thirty patients (68%) completed four 
cycles of chemotherapy, whereas three patients received three 
cycles, seven patients received two cycles, and four patients 
TABLE 1.  Patient Characteristics
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aClinical stage was based on the 5th edition of the tumor, node, metastasis staging 
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received one cycle. Reasons for the discontinuation of the pro-
tocol treatment for the four patients who received only one 
cycle included progressive disease (n = 2), deterioration of 
PS (n = 1), and liver dysfunction prolonged for more than 2 
weeks (n = 1). The median of relative dose intensity for CDDP 
or CPT was 94.3% (range, 66.2%–102.1%) and 82.4% (range, 
33.3%–100%), respectively.
Twenty-four partial responses were seen among the 44 
eligible patients, yielding an objective RR of 54.5% (95% 
confidence interval [CI], 38.8%–69.6%; Table 2). All 24 
responders received four cycles of chemotherapy. Of them, 
eight patients received full planned dose of chemotherapy. The 
dose intensity of CDDP or CPT was not associated with RR 
(data not shown).
Figure 1 shows the OS curve for all 44 eligible patients. 
At 8 months after the last enrollment, the median survival 
time (MST) was 15.1 months (95% CI, 11.2–19.0 months). 
The 1-year and 2-year survival rates for all 44 eligible patients 
were 62.1% and 18.4%, respectively. The median PFS was 5.9 
months (95% CI, 5.5–6.3 months; Fig. 2).
Toxicity was evaluated in all eligible patients. The most 
common toxicity was neutropenia (Table 3). Twenty-four 
patients (55%) experienced grade 3 or 4 neutropenia, but 
only three patients (7%) developed neutropenic fever. Three 
patients (7%) developed grade 3 infection with neutropenia, 
and another three patients (7%) developed grade 3 infection 
without neutropenia. Two patients (5%) developed grade 3 
diarrhea. No treatment-related deaths occurred in this series.
TABLE 2.  Efficacy of Combination Chemotherapy with Irinotecan and Cisplatin
All Patients (N = 44)
Central Pathological Review (n = 40)
Large-Cell Neuroendocrine  
Carcinoma (n = 30) SCLC (n = 10)
Type of Response
No. of  
Patients %
No. of  
Patients %
No. of  
Patients %
CR 0 0 0 0 0 0
PR 24 54.5 14 46.7 8 80
CR + PR 24 54.5 14 46.7 8 80
95%CI 38.8–69.6 28.3–65.7 44.4–97.5
Stable disease 12 27.3 10 33.3 1 10
Progression 7 15.9 6 20 1 10
Not evaluable 1 2.3 0 0 0 0
Median progression-free survival (mo) (95%CI) 5.9 (5.5–6.3) 5.8 (3.8–7.8) 6.2 (5.2–7.2)
Median survival time (mo) (95%CI) 15.1 (11.2–19.0) 12.6 (9.3–16.0) 17.3 (11.2–23.3)
Four patients of 14 responders in the large-cell neuroendocrine carcinoma group and four patients of eight responders in the SCLC group received full planned dose of chemotherapy.




Toxicity Toxicity Grade % 3–4
1 2 3 4
Leukopenia 8 16 6 4 23
Neutropenia 3 9 11 13 55
Anemia 18 18 6 1 16
Thrombocytopenia 13 2 0 0 0
Febrile neutropenia — — 3 0 7
Bilirubin 6 2 0 1 2
AST 13 2 2 0 5
ALT 14 1 2 0 5
Creatinine 10 2 1 0 2
Hyponatremia 27 0 4 1 11
Hypokalemia 9 0 1 0 2
Hyperkalemia 10 1 1 0 2
Nausea 17 9 3 — 7
Vomiting 8 4 1 0 2
Appetite loss 21 12 3 0 7
Diarrhea 17 12 2 0 5
General fatigue 17 7 2 0 5
Constipation 3 2 0 0 0
Alopecia 17 9 0 0 0
Infection with neutropenia 1 0 3 0 7
Infection without neutropenia 1 1 3 0 7
Fever (noninfectious) 5 1 0 0 0
AST, aspartate transaminase; ALT, alanine tranferase.
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A total of 36 patients (82%) received second-line che-
motherapy. Twenty-five patients received amrubicin, four 
patients received platinum-based chemotherapy (CDDP + 
CPT [n = 2], CDDP + etoposide [n = 1], and carboplatin + 
paclitaxel [n = 1]), and six patients received docetaxel.
Pathological specimens for central review were avail-
able in 41 patients. Pathological specimens in three patients 
were not available because these specimens were returned to 
other institutions, where biopsy was conducted. Thirty patients 
were diagnosed as having LCNEC, whereas 10 patients were 
diagnosed as having SCLC, and one patient was diagnosed as 
having NSCLC with a neuroendocrine structure. The RR was 
47% (95% CI, 28.3%–65.7%) for patients diagnosed as having 
LCNEC and 80% (95% CI, 44.4%–97.5%) for patients diag-
nosed as having SCLC (p = 0.082). The median PFS was 5.8 
months (95% CI, 3.8–7.8 months) in the LCNEC group and 6.2 
months (95% CI, 5.2–7.2 months) in the SCLC group (p = 0.382) 
(Fig. 3A). The MST was 12.6 months (95% CI, 9.3–16.0 
months) in the LCNEC group and 17.3 months (95% CI, 11.2–
23.3 months) in the SCLC group (p = 0.047) (Fig. 3B).
DISCUSSION
This trial is the first to evaluate the use of combination 
chemotherapy consisting of CPT and CDDP prospectively in 
patients with advanced LCNEC. The lower limit of the CI for 
the RR exceeded 30%, which was the predefined threshold. 
The MST was 15.1 months (95% CI, 11.2–19.0 months), and 
the median PFS was 5.9 months (95% CI, 5.5–6.3 months). 
LCNEC is currently categorized as a variant form of large-cell 
carcinoma, that is NSCLC, but LCNEC has neuroendocrine 
features, similar to SCLC. Combination chemotherapy 
consisting of CPT and CDDP seems to be promising as a first-
line chemotherapy for patients with advanced LCNEC.
According to the central pathological review, which was 
blinded to all clinical information, 30 patients (73%) were 
diagnosed as having LCNEC, and 10 patients (24%) were 
diagnosed as having SCLC. The PFS was similar between the 
LCNEC and SCLC patients; however, the OS of the SCLC 
patients was significantly longer than that of the LCNEC 
patients. The RR was also superior in the SCLC patients. A 
previous retrospective study examined the clinical outcome of 
the patients with high-grade neuroendocrine carcinoma, prob-
able LCNEC, which was diagnosed on the basis of biopsy 
results. The RR for second-line chemotherapy was 17% 
among the patients with HGNEC-probable LCNEC (2/12), 
and 43% among the patients with SCLC (45 of 102) (p = 
0.12).15 The chemosensitivity of LCNEC is considered to be 
lower than that of SCLC, especially in response to second-line 
chemotherapy. Consequently, the OS of the LCNEC patients 
was inferior to that of the SCLC patients.
The present study had several limitations. First, only 
30 patients (73%) were diagnosed as having LCNEC, based 
on a central review. The RR in these 30 patients was 47% 
(95% CI, 28.3%– 65.7%). Thus, the lower limit of the 
95%CI for the RR did not exceed the predefined threshold 
of 30%. Second, data regarding the efficacy of second-line 
chemotherapy were not available. We could not confirm the 
chemoresistance of LCNEC in second-line chemotherapy, 
compared with that of SCLC. Third, the number of patients 
included in the study was small. The enrollment period 
exceeded 6 years despite the multicenter design. The rela-
tively low incidence of LCNEC and the difficulty of diag-
nosing LCNEC pathologically using small biopsy specimens 
was responsible for the slow accrual.
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